RANI
Rani Therapeutics Holdings, Inc. NASDAQ Listed Jul 30, 2021$0.93
Mkt Cap $60.8M
52w Low $0.39
15.6% of range
52w High $3.87
50d MA $1.05
200d MA $1.11
P/E (TTM)
-2.1x
EV/EBITDA
-2.0x
P/B
1.5x
Debt/Equity
0.1x
ROE
-124.0%
P/FCF
-4.7x
RSI (14)
—
ATR (14)
—
Beta
0.66
50d MA
$1.05
200d MA
$1.11
Avg Volume
1.1M
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
CIK (SEC)
Phone
408 457 3700
2051 Ringwood Avenue · San Jose, CA 95131 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | AMC | -0.03 | -0.07 | -133.3% | 1.08 | -2.8% | -24.9% | -5.9% | -3.7% | +9.6% | +4.3% | — |
| Nov 6, 2025 | AMC | -0.09 | -0.12 | -33.3% | 2.27 | -14.1% | -11.0% | -7.9% | +4.3% | +9.3% | -9.0% | — |
| Aug 7, 2025 | AMC | -0.19 | -0.18 | +5.3% | 0.53 | -2.4% | -0.9% | -5.3% | +6.2% | -0.6% | +5.5% | — |
| May 13, 2025 | AMC | -0.22 | -0.22 | +0.0% | 0.48 | +16.0% | +15.6% | +2.5% | +12.2% | +9.3% | +7.0% | — |
| Mar 31, 2025 | AMC | -0.24 | -0.27 | -12.5% | 1.26 | -0.8% | -2.4% | +13.0% | -6.5% | -6.9% | -7.4% | — |
| Nov 14, 2024 | AMC | -0.22 | -0.24 | -9.1% | 2.35 | +0.9% | -3.4% | -9.7% | +0.5% | -0.5% | -0.5% | — |
| Aug 6, 2024 | AMC | -0.29 | -0.26 | +10.3% | 2.50 | +1.2% | -2.8% | -0.8% | -6.2% | +4.9% | +13.9% | — |
| May 6, 2024 | AMC | -0.23 | -0.29 | -26.1% | 7.56 | -0.1% | -1.3% | -4.2% | -5.2% | -6.9% | -3.2% | — |
| Mar 20, 2024 | AMC | -0.31 | -0.27 | +12.9% | 3.57 | +0.8% | +0.8% | -9.4% | -0.6% | -1.9% | -4.7% | — |
| Nov 8, 2023 | AMC | -0.47 | -0.36 | +23.4% | 1.98 | -2.0% | -3.0% | +3.1% | -1.5% | +1.3% | +0.8% | — |
| Aug 11, 2023 | AMC | -0.40 | -0.37 | +7.5% | 4.20 | +2.4% | +4.5% | -2.5% | -2.8% | -3.6% | +2.2% | — |
| May 10, 2023 | AMC | -0.47 | -0.33 | +29.8% | 4.30 | +0.2% | -8.8% | +2.6% | +2.0% | -0.5% | +12.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 1 | Canaccord Genuity | Maintains | Buy → Buy | — | $0.73 | $0.74 | +0.8% | +9.6% | +4.3% | -1.2% | -1.5% | +1.7% |
| Mar 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.08 | $1.05 | -2.8% | -24.9% | -5.9% | -3.7% | +9.6% | +4.3% |
| Jan 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.39 | $1.41 | +1.4% | +0.7% | +6.4% | -4.7% | -1.4% | -0.7% |
| Oct 20 | Maxim Group | Maintains | Buy → Buy | — | $1.64 | $2.10 | +28.0% | +37.2% | +26.7% | -15.1% | -13.6% | -12.9% |
| May 16 | Oppenheimer | Maintains | Outperform → Outperform | — | $0.57 | $0.57 | -0.1% | +12.2% | +9.3% | +7.0% | -5.5% | -8.5% |
| Apr 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.39 | $1.30 | -6.5% | -6.5% | -6.9% | -7.4% | -5.4% | +18.9% |
| Feb 26 | Canaccord Genuity | Maintains | Buy → Buy | — | $1.47 | $1.45 | -1.4% | +4.8% | -2.6% | +2.0% | -3.9% | -2.7% |
| Feb 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.65 | $1.60 | -3.0% | -7.9% | -6.6% | -0.7% | +19.9% | +8.9% |
| Nov 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.05 | $2.03 | -1.0% | +0.5% | -0.5% | -0.5% | +2.0% | +0.0% |
| Oct 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.63 | $2.64 | +0.4% | +1.9% | -4.1% | -7.4% | +5.9% | -5.2% |
| Aug 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.68 | $2.62 | -2.2% | +4.1% | +2.5% | +0.3% | +1.4% | +5.5% |
| Jun 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.11 | $4.11 | +0.0% | -9.0% | +4.0% | +1.3% | -3.6% | +0.5% |
| May 9 | BTIG | Maintains | Buy → Buy | — | $7.15 | $7.23 | +1.1% | -5.2% | -6.9% | -3.2% | -5.4% | -4.3% |
| May 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.56 | $7.55 | -0.1% | -1.3% | -4.2% | -5.2% | -6.9% | -3.2% |
| Mar 27 | Canaccord Genuity | Maintains | Buy → Buy | — | $3.18 | $3.03 | -4.7% | -4.7% | +2.6% | +0.6% | +0.3% | +5.4% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.26 | $3.22 | -1.2% | -0.6% | -1.9% | -4.7% | +2.6% | +0.6% |
| Feb 6 | Wedbush | Maintains | Outperform → Outperform | — | $3.69 | $3.80 | +3.0% | +1.9% | +0.8% | +0.3% | -0.3% | -5.8% |
| Nov 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.98 | $1.94 | -2.0% | -3.0% | +3.1% | -1.5% | +1.3% | +0.8% |
| Sep 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.95 | $2.95 | +0.0% | -6.1% | +6.9% | -6.1% | -0.7% | +6.9% |
| Sep 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.75 | $3.75 | +0.0% | -0.8% | -7.3% | -10.7% | -1.0% | -4.3% |
| Aug 21 | BofA Securities | Maintains | Buy → Buy | — | $4.10 | $4.04 | -1.5% | -3.7% | -3.8% | +1.1% | +3.1% | -3.8% |
| Aug 17 | Wedbush | Maintains | Outperform → Outperform | — | $4.16 | $4.25 | +2.2% | -3.6% | +2.2% | -3.7% | -3.8% | +1.1% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.20 | $4.30 | +2.4% | +4.5% | -2.5% | -2.8% | -3.6% | +2.2% |
| Jun 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.63 | $4.64 | +0.2% | +6.5% | -3.0% | +3.6% | +1.8% | -5.8% |
| May 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.30 | $4.31 | +0.2% | -8.8% | +2.6% | +2.0% | -0.5% | +12.3% |
No insider trades available.
Data updated apr 26, 2026 9:53pm
· Source: massive.com